Report cover image

APAC Stroke Market - Industry Trends and Forecast to 2031

Publisher Data Bridge Market Research
Published Oct 01, 2023
Length 389 Pages
SKU # DAABD18360529

Description

APAC Stroke Market - Industry Trends and Forecast to 2031


Europe stroke market is projected to register a CAGR of 7.2% in the forecast period of 2023 to 2030. The new market report contains data for historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.
Market Segmentation:
Europe Stroke Market, By Type (Ischemic Stroke, Transient Ischemic Attack (TIA) and Hemorrhage Stroke), Diagnosis (Imaging Test, Blood Test, Echocardiogram, Lumbar Puncture, and Other), Treatment (Medication, Other Therapy, and Surgery), Gender (Female and Male), End-User (Hospitals & Clinics, Specialty Clinics, Ambulatory Surgical Centers, Homecare, Laboratories and Others), Distribution Channel (Direct Tender, Retail Sales And Online Sales) Country (Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland and Rest of Europe) – Industry trends and forecast to 2030
Overview of Europe Stroke Market Dynamics

Drivers
• Rising incidences of stroke
• Increasing number of patients with hypertension and coronary heart diseases

Restraints

• High cost associated with treatment of stroke
• Side-effects associated with medication

Opportunities

• Expansion of telemedicine and remote monitoring
• Innovative therapies in pipeline for stroke treatment
Market Players
Some of the major market players operating in the Europe stroke market are:
• Bristol-Myers Squibb Company
• Boehringer Ingelheim International GmbH.
• F. Hoffmann-La Roche Ltd
• DAIICHI SANKYO COMPANY, LIMITED.
• Sanofi
• Johnson & Johnson Services, Inc.
• Bayer AG
• Sandoz AG
• Pfizer Inc.
• Medtronic
• Abbott
• Viatris Inc.
• AstraZeneca
• Penumbra, Inc.
• GLENMARK PHARMACEUTICALS LTD
• Fresenius Kabi USA

Table of Contents

389 Pages
1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of The Europe Stroke Market
1.4 Limitations
1.5 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Geographical Scope
2.3 Years Considered For The Study
2.4 Currency And Pricing
2.5 Dbmr Tripod Data Validation Model
2.6 Multivariate Modelling
2.7 Type Lifeline Curve
2.8 Primary Interviews With Key Opinion Leaders
2.9 Dbmr Market Position Grid
2.10 Market Application Coverage Grid
2.11 Vendor Share Analysis
2.12 Secondary Sources
2.13 Assumptions
3 Executive Summary
4 Premium Insights
4.1 Pestel's Model
4.2 Porter's 5 Forces
5 Epidemiology
6 Europe Stroke Market, Regulatory Framework
6.1 Regulation In U.S
6.2 Regulation In Europe
6.3 Regulation In China
6.4 Regulation In Japan
6.5 Regulation In South Africa 70 
7 Market Overview
7.1 Drivers
7.1.1 Rising Incidences Of Stroke
7.1.2 Increasing Number Of Patients With Hypertension And Coronary Heart Diseases
7.1.3 Increasing Diabetic And Obese Population
7.1.4 Advancements In Medical Technology For Stroke Treatment
7.2 Restraints
7.2.1 High Cost Associated With Treatment Of Stroke
7.2.2 Side-effects Associated With Medication
7.3 Opportunities
7.3.1 Expansion Of Telemedicine And Remote Monitoring
7.3.2 Innovative Therapies In Pipeline For Stroke Treatment
7.4 Challenges
7.4.1 Inaccurate Diagnosis Of Strokes S
7.4.2 Complications In Managing Stroke In Patients With Multiple Chronic Conditions
8 Europe Stroke Market, By Type
8.1 Overview
8.2 Ischemic Stroke
8.2.1 Thrombotic (Cerebral Thrombosis)
8.2.2 Embolic (Cerebral Embolism)
8.3 Hemorrhagic Stroke
8.3.1 Subarachnoid Hemorrhage
8.3.2 Intracerebral Hemorrhage
8.4 Transient Ischemic Attack (Tia)
9 Europe Stroke Market, By Treatment
9.1 Overview
9.2 Medication
9.2.1 By Class
9.2.1.1 Blood Pressure Medicines
9.2.1.1.1 Angiotensin-converting Enzyme (Ace) Inhibitors
9.2.1.1.1.1 Ramipril
9.2.1.1.1.2 Lisinopril
9.2.1.1.1.3 Enalapril
9.2.1.1.1.4 Perindopril
9.2.1.1.1.5 Other 98 
9.2.1.1.2 Diuretics
9.2.1.1.2.1 Indapamide
9.2.1.1.2.2 Bendroflumethiazide
9.2.1.1.2.3 Spironolactone
9.2.1.1.2.4 Amiloride
9.2.1.1.2.5 Other
9.2.1.1.3 Calcium Channel Blockers
9.2.1.1.3.1 Amlodipine
9.2.1.1.3.2 Nifedipine
9.2.1.1.3.3 Verapamil
9.2.1.1.3.4 Nicardipine
9.2.1.1.3.5 Felodipine
9.2.1.1.3.6 Nimodipine
9.2.1.1.3.7 Other
9.2.1.1.4 Beta Blockers
9.2.1.1.4.1 Atenolol
9.2.1.1.4.2 Bisoprolol
9.2.1.1.4.3 Labetolol
9.2.1.1.4.4 Other
9.2.1.1.5 Alpha Blockers
9.2.1.1.5.1 Doxazosin
9.2.1.1.5.2 Other
9.2.1.1.6 Others
9.2.1.1 Antiplatelet Drugs
9.2.1.1.1 Aspirin
9.2.1.1.2 Clopidogrel
9.2.1.1.3 Dipyridamole
9.2.1.1.4 Ticlopidine
9.2.1.1.5 Others
9.2.1.2 Anticoagulants
9.2.1.2.1 Warfarin
9.2.1.2.2 Apixaban
9.2.1.2.3 Dabigatran
9.2.1.2.4 Heparin
9.2.1.2.5 Rivaroxaban
9.2.1.2.6 Others
9.2.1.3 Tissue Plasminogen Activator (Tpa)
9.2.1.3.1 Alteplase
9.2.1.3.2 Tenecteplase
9.2.1.3.3 Reteplase
9.2.1.3.4 Anistreplase
9.2.1.3.5 Others
9.2.1.4 Statins
9.2.1.4.1 Atorvastatin
9.2.1.4.2 Simvastatin
9.2.1.4.3 Lovastatin
9.2.1.4.4 Rosuvastatin
9.2.1.4.5 Fluvastatin
9.2.1.4.6 Pravastatin
9.2.1.4.7 Pitavastatin
9.2.1.4.8 Others
9.2.1.5 Vitamin K
9.2.1.6 Supportive Medication
9.2.1.6.1 Nutritional Supplements
9.2.1.6.2 Antipyretics
9.2.1.6.3 Others
9.2.2 By Drug Type
9.2.2.1 Generics
9.2.2.2 Branded
9.2.2.2.1 Eliquis
9.2.2.2.2 Pradaxa
9.2.2.2.3 Activase
9.2.2.2.4 Aspirin
9.2.2.2.5 Plavix
9.2.2.2.6 Aggrenox
9.2.2.2.7 Others
9.2.3 By Route Of Administration
9.2.3.1 Oral
9.2.3.1.1 Tablet
9.2.3.1.2 Capsules
9.2.3.1.3 Others
9.2.3.2 Parenteral
9.2.3.2.1 Intravenous
9.2.3.2.2 Subcutaneous
9.2.3.3 Others
9.2.4 By Mode Of Purchase
9.2.4.1 Prescription
9.2.4.2 Over The Counter (Otc) 115 
9.2.5 By Therpay Type
9.2.5.1 Combination Therapy
9.2.5.2 Monotherapy
9.3 Surgery
9.3.1 Embolic Coils
9.3.2 Aspiration Catheters
9.3.3 Stent Retriever
9.3.4 Surgical Clipping
9.3.5 Others
9.4 Other Therapy
9.4.1 Physical Therapy
9.4.2 Occupational Therapy
9.4.3 Speech Therapy
9.4.4 Others
10 Europe Stroke Market, By Diagnosis
10.1 Overview
10.2 Imaging Test
10.2.1 Computerized Tomography (Ct) Scan
10.2.2 Magnetic Resonance Imaging (Mri)
10.2.3 Carotid Ultrasound
10.2.4 Cerebral Angiogram
10.3 Blood Test
10.4 Echocardiogram
10.5 Lumbar Puncture
10.6 Others
11 Europe Stroke Market, By Gender
11.1 Overview
11.2 Female
11.3 Male
12 Europe Stroke Market, By End User
12.1 Overview
12.2 Hospitals & Clinics
12.3 Specialty Clinics
12.4 Ambulatory Surgical Center
12.5 Homecare
12.6 Laboratories
12.7 Others 142 
13 Europe Stroke Market, By Distribution Channel
13.1 Overview
13.2 Direct
13.3 Retail
13.4 Online
14 Europe Stroke Market, By Region
14.1 Europe
14.1.1 Germany
14.1.2 U.K.
14.1.3 France
14.1.4 Russia
14.1.5 Italy
14.1.6 Spain
14.1.7 Turkey
14.1.8 Poland
14.1.9 Belgium
14.1.10 Netherlands
14.1.11 Switzerland
14.1.12 Denmark
14.1.13 Sweden
14.1.14 Norway
14.1.15 Finland
14.1.16 Rest Of Europe
15 Europe Stroke Market, Company Landscape
15.1 Company Share Analysis: Europe
16 Swot Analysis
17 Company Profiles
17.1 Bristol-myers Squibb Company
17.1.1 Company Snapshot
17.1.2 Revenue Analysis
17.1.3 Company Share Analysis
17.1.4 Product Portfolio
17.1.5 Recent Development 341 
17.2 Boehringer Ingelheim International Gmbh
17.2.1 Company Snapshot
17.2.2 Product Portfolio
17.2.3 Company Share Analysis
17.2.4 Recent Development
17.3 F. Hoffmann-la Roche Ltd
17.3.1 Company Snapshot
17.3.2 Revenue Analysis
17.3.3 Company Share Analysis
17.3.4 Product Portfolio
17.3.5 Recent Development
17.4 Daiichi Sankyo Company, Limited
17.4.1 Company Snapshot
17.4.2 Revenue Analysis
17.4.3 Company Share Analysis
17.4.4 Product Portfolio
17.4.5 Recent Development
17.5 Sanofi
17.5.1 Company Snapshot
17.5.2 Revenue Analysis
17.5.3 Company Share Analysis
17.5.4 Product Portfolio
17.5.5 Recent Development
17.6 Abbott
17.6.1 Company Snapshot
17.6.2 Revenue Analysis
17.6.3 Product Portfolio
17.6.4 Recent Development
17.7 Amneal Pharmaceuticals Llc
17.7.1 Company Snapshot
17.7.2 Revenue Analysis
17.7.3 Product Portfolio
17.7.4 Recent Development
17.8 Astrazeneca
17.8.1 Company Snapshot
17.8.2 Revenue Analysis
17.8.3 Product Portfolio
17.8.4 Recent Development 17.9 Bayer Ag
17.9.1 Company Snapshot
17.9.2 Revenue Analysis
17.9.3 Product Portfolio
17.9.4 Recent Development
17.10 Fresenius Se & Co. Kgaa
17.10.1 Company Snapshot
17.10.2 Revenue Analysis
17.10.3 Product Portfolio
17.10.4 Recent Development
17.11 Glenmark Pharmaceuticals Ltd.
17.11.1 Company Snapshot
17.11.2 Revenue Analysis
17.11.3 Product Portfolio
17.11.4 Recent Development
17.12 Johnson & Johnson Services, Inc.
17.12.1 Company Snapshot
17.12.2 Revenue Analysis
17.12.3 Product Portfolio
17.12.4 Recent Development
17.13 Lupin
17.13.1 Company Snapshot
17.13.2 Revenue Analysis
17.13.3 Product Portfolio
17.13.4 Recent Development
17.14 Medtronic
17.14.1 Company Snapshot
17.14.2 Revenue Analysis
17.14.3 Product Portfolio
17.14.4 Recent Development
17.15 Oxford Laboratories Pvt. Ltd.
17.15.1 Company Snapshot
17.15.2 Product Portfolio
17.15.3 Recent Development
17.16 Penumbra, Inc.
17.16.1 Company Snapshot
17.16.2 Revenue Analysis
17.16.3 Product Portfolio
17.16.4 Recent Development 17.17 Pfizer Inc.
17.17.1 Company Snapshot
17.17.2 Revenue Analysis
17.17.3 Product Portfolio
17.17.4 Recent Development
17.18 Sandoz Group Ag (Subsidiary Of Novartis Ag)
17.18.1 Company Snapshot
17.18.2 Revenue Analysis
17.18.3 Product Portfolio
17.18.4 Recent Development
17.19 Teva Pharmaceuticals Usa, Inc.
17.19.1 Company Snapshot
17.19.2 Revenue Analysis
17.19.3 Product Portfolio
17.19.4 Recent Development
17.20 Viatris Inc.
17.20.1 Company Snapshot
17.20.2 Revenue Analysis
17.20.3 Product Portfolio
17.20.4 Recent Development
18 Questionnaire
19 Related Reports
List Of Tables
Table 1 Europe Stroke Market, By Type, 2022-2030 (Usd Thousand)
Table 2 Europe Ischemic Stroke In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 3 Europe Ischemic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
Table 4 Europe Hemorrhagic Stroke In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 5 Europe Hemorrhagic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
Table 6 Europe Transient Ischemic Attack (Tia) In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 7 Europe Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
Table 8 Europe Medication In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 9 Europe Medication In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 10 Europe Blood Pressure Medicines In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 11 Europe Angiotensin-converting Enzyme (Ace) Inhibitors In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 12 Europe Diuretics In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 13 Europe Calcium Channel Blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 14 Europe Beta Blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 15 Europe Alpha Blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 16 Europe Antiplatelet Drugs In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 17 Europe Anticoagulants In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 18 Europe Tissue Plasminogen Activator (Tpa) In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 19 Europe Statins In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 20 Europe Supportive Medication In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 21 Europe Medication In Stroke Market, By Drug Type, 2021-2030 (Usd Thousand)
Table 22 Europe Branded In Stroke Market, By Drug Type, 2021-2030 (Usd Thousand)
Table 23 Europe Medication In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 24 Europe Oral In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 25 Europe Parenteral In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 26 Europe Medication In Stroke Market, By Mode Of Purchase, 2021-2030 (Usd Thousand)
Table 27 Europe Medication In Stroke Market, By Therapy Type, 2021-2030 (Usd Thousand)
Table 28 Europe Surgery In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 29 Europe Surgery In Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
Table 30 Europe Other Therapy In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 31 Europe Other Therapy In Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
Table 32 Europe Stroke Market, By Diagnosis, 2021-2030 (Usd Thousand)
Table 33 Europe Imaging Test In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 34 Europe Imaging Test In Stroke Market, By Type, 2021-2030 (Usd Thousand)
Table 35 Europe Blood Test In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 36 Europe Echocardiogram In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 37 Europe Lumbar Puncture In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 38 Europe Others In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 39 Europe Stroke Market, By Gender, 2021-2030 (Usd Thousand)
Table 40 Europe Female In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 41 Europe Male In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 42 Europe Stroke Market, By End User, 2021-2030 (Usd Thousand)
Table 43 Europe Hospitals & Clinics In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 44 Europe Specialty Clinics In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 45 Europe Ambulatory Surgical Center In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 46 Europe Homecare In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 47 Europe Laboratories In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 48 Europe Others In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 49 Europe Stroke Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 50 Europe Direct In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 51 Europe Retail In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 52 Europe Online In Stroke Market, By Region, 2021-2030 (Usd Thousand)
Table 53 Europe Stroke Market, By Country, 2021-2030 (Usd Thousand)
Table 54 Europe Stroke Market, By Type, 2021-2030 (Usd Thousand)
Table 55 Europe Ischemic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
Table 56 Europe Hemorrhagic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
Table 57 Europe Stroke Market, By Diagnosis And Treatment, 2021-2030 (Usd Thousand)
Table 58 Europe Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
Table 59 Europe Medication In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 60 Europe Blood Pressure Medicine In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 61 Europe Angiotensin-converting Enzyme (Ace) Inhibitors In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 62 Europe Diuretics In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 63 Europe Calcium Channel Blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 64 Europe Beta Blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 65 Europe Alpha-blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 66 Europe Antiplatelet Drugs In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 67 Europe Anticoagulants In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 68 Europe Tissue Plasminogen Activator (Tpa) In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 69 Europe Statins In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 70 Europe Supportive Medication In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 71 Europe Medication In Stroke Market, By Drug Type, 2021-2030 (Usd Thousand)
Table 72 Europe Branded In Stroke Market, By Drug Type, 2021-2030 (Usd Thousand)
Table 73 Europe Medication In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 74 Europe Oral In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 75 Europe Parenteral In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 76 Europe Medication In Stroke Market, By Mode Of Purchase, 2021-2030 (Usd Thousand)
Table 77 Europe Medication In Stroke Market, By Therapy Type, 2021-2030 (Usd Thousand)
Table 78 Europe Surgery In Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
Table 79 Europe Other Therapy In Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
Table 80 Europe Stroke Market, By Diagnosis, 2021-2030 (Usd Thousand)
Table 81 Europe Imaging Test In Stroke Market, By Type, 2021-2030 (Usd Thousand)
Table 82 Europe Stroke Market, By Gender, 2021-2030 (Usd Thousand)
Table 83 Europe Stroke Market, By End User, 2021-2030 (Usd Thousand)
Table 84 Europe Stroke Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 85 Germany Stroke Market, By Type, 2021-2030 (Usd Thousand)
Table 86 Germany Ischemic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
Table 87 Germany Hemorrhagic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
Table 88 Germany Stroke Market, By Diagnosis And Treatment, 2021-2030 (Usd Thousand)
Table 89 Germany Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
Table 90 Germany Medication In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 91 Germany Blood Pressure Medicine In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 92 Germany Angiotensin-converting Enzyme (Ace) Inhibitors In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 93 Germany Diuretics In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 94 Germany Calcium Channel Blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 95 Germany Beta Blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 96 Germany Alpha-blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 97 Germany Antiplatelet Drugs In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 98 Germany Anticoagulants In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 99 Germany Tissue Plasminogen Activator (Tpa) In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 100 Germany Statins In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 101 Germany Supportive Medication In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 102 Germany Medication In Stroke Market, By Drug Type, 2021-2030 (Usd Thousand)
Table 103 Germany Branded In Stroke Market, By Drug Type, 2021-2030 (Usd Thousand)
Table 104 Germany Medication In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 105 Germany Oral In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 106 Germany Parenteral In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 107 Germany Medication In Stroke Market, By Mode Of Purchase, 2021-2030 (Usd Thousand)
Table 108 Germany Medication In Stroke Market, By Therapy Type, 2021-2030 (Usd Thousand)
Table 109 Germany Surgery In Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
Table 110 Germany Other Therapy In Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
Table 111 Germany Stroke Market, By Diagnosis, 2021-2030 (Usd Thousand)
Table 112 Germany Imaging Test In Stroke Market, By Type, 2021-2030 (Usd Thousand)
Table 113 Germany Stroke Market, By Gender, 2021-2030 (Usd Thousand)
Table 114 Germany Stroke Market, By End User, 2021-2030 (Usd Thousand)
Table 115 Germany Stroke Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 116 U.K. Stroke Market, By Type, 2021-2030 (Usd Thousand)
Table 117 U.K. Ischemic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
Table 118 U.K. Hemorrhagic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
Table 119 U.K. Stroke Market, By Diagnosis And Treatment, 2021-2030 (Usd Thousand)
Table 120 U.K. Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
Table 121 U.K. Medication In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 122 U.K. Blood Pressure Medicine In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 123 U.K. Angiotensin-converting Enzyme (Ace) Inhibitors In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 124 U.K. Diuretics In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 125 U.K. Calcium Channel Blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 126 U.K. Beta Blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 127 U.K. Alpha-blockers In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 128 U.K. Antiplatelet Drugs In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 129 U.K. Anticoagulants In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 130 U.K. Tissue Plasminogen Activator (Tpa) In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 131 U.K. Statins In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 132 U.K. Supportive Medication In Stroke Market, By Class, 2021-2030 (Usd Thousand)
Table 133 U.K. Medication In Stroke Market, By Drug Type, 2021-2030 (Usd Thousand)
Table 134 U.K. Branded In Stroke Market, By Drug Type, 2021-2030 (Usd Thousand)
Table 135 U.K. Medication In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 136 U.K. Oral In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 137 U.K. Parenteral In Stroke Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 138 U.K. Medication In Stroke Market, By Mode Of Purchase, 2021-2030 (Usd Thousand)
Table 139 U.K. Medication In Stroke Market, By Therapy Type, 2021-2030 (Usd Thousand)
Table 140 U.K. Surgery In Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
Table 141 U.K. Other Therapy In Stroke Market, By Treatment, 2021-2030 (Usd Thousand)
Table 142 U.K. Stroke Market, By Diagnosis, 2021-2030 (Usd Thousand)
Table 143 U.K. Imaging Test In Stroke Market, By Type, 2021-2030 (Usd Thousand)
Table 144 U.K. Stroke Market, By Gender, 2021-2030 (Usd Thousand)
Table 145 U.K. Stroke Market, By End User, 2021-2030 (Usd Thousand)
Table 146 U.K. Stroke Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 147 France Stroke Market, By Type, 2021-2030 (Usd Thousand)
Table 148 France Ischemic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
Table 149 France Hemorrhagic Stroke In Stroke Market, By Type, 2021-2030 (Usd Thousand)
List Of Figures
Figure 1 Europe Stroke Market: Segmentation
Figure 2 Europe Stroke Market: Data Triangulation
Figure 3 Europe Stroke Market: Droc Analysis
Figure 4 Europe Stroke Market : Europe Vs Regional Market Analysis
Figure 5 Europe Stroke Market: Company Research Analysis
Figure 6 Europe Stroke Market: Interview Demographics
Figure 7 Europe Stroke Market: Dbmr Market Position Grid
Figure 8 Europe Stroke Market: Market Application Coverage Grid
Figure 9 Europe Stroke Market: Vendor Share Analysis
Figure 10 Europe Stroke Market: Segmentation
Figure 11 Increasing Number Of Patients With Hypertension And Coronary Heart Disease Is Expected To Drive The Europe Stroke Market Growth In The Forecast Period Of 2023 To 2030
Figure 12 Ischemic Stroke Segment Is Expected To Account For The Largest Share Of The Europe Stroke Market In The Forecast Period Of 2023 & 2030
Figure 13 Drivers, Restraints, Opportunities, And Challenges Of The Europe Stroke Market
Figure 14 Europe Stroke Market: By Type, 2022
Figure 15 Europe Stroke Market: By Type, 2023-2030 (Usd Thousand)
Figure 16 Europe Stroke Market: By Type, Cagr (2023-2030)
Figure 17 Europe Stroke Market: By Type, Lifeline Curve
Figure 18 Europe Stroke Market: By Treatment, 2022
Figure 19 Europe Stroke Market: By Treatment, 2023-2030 (Usd Million)
Figure 20 Europe Stroke Market: By Treatment, Cagr (2023-2030)
Figure 21 Europe Stroke Market: By Treatment, Lifeline Curve
Figure 22 Europe Stroke Market: By Diagnosis, 2022
Figure 23 Europe Stroke Market: By Diagnosis, 2023-2030 (Usd Thousand)
Figure 24 Europe Stroke Market: By Diagnosis, Cagr (2023-2030)
Figure 25 Europe Stroke Market: By Diagnosis, Lifeline Curve
Figure 26 Europe Stroke Market: By Gender, 2022
Figure 27 Europe Stroke Market: By Gender, 2023-2030 (Usd Thousand)
Figure 28 Europe Stroke Market: By Gender, Cagr (2023-2030)
Figure 29 Europe Stroke Market: By Gender, Lifeline Curve
Figure 30 Europe Stroke

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us